MSInsight is a precision oncology startup specalizing in the detection of biomarkers to guide cancer treatment. Our flagship solution, MSIcare, uses advanced AI and next generation sequencing, NGS, to detect microsatellite instability, an essential biomarker for immunotherapy response. By analyzing the DNA repair functionality of tumor cells, MSIcare helps identify patients who are most likely to benefit from targeted therapies. Currently in testing with leading laboratories in France and the United States, MSIcare offers fast, reliable, and cost effective results. MSInsight also provides expert bioinformatics support and data interpretation services for clinical labs. Our mission is to accelerate access to personalized medicine by transforming complex genomic data into actionable insights for clinicians. Based in Lyon and Paris, MSInsight combines scientific rigor with technological innovation to improve cancer care worldwide.